News | March 18, 2026
Sun Pharma scores FDA review for ILUMYA in psoriatic arthritis
ILUMYA has already earned FDA approvals for scalp and nail plaque psoriasis in April 2024 and December 2025
ILUMYA has already earned FDA approvals for scalp and nail plaque psoriasis in April 2024 and December 2025
The expanded ownership is expected to improve access to Cialis for millions of men in Asia affected by ED and BPH
Neupharma gains exclusive rights to develop and commercialize corticorelin for peritumoral brain edema
The move comes as the global biotech and biopharma CDMO market continues to surge, fueled by rising demand
The protections extend through at least 2035, with the potential for further extensions
The initiative provides clearer regulatory guidance and a defined path from research in space to patient access on Earth
Cognita CXR leverages a proprietary vision-language model to analyze full chest X-ray studies and generate comprehensive preliminary findings
Enhertu recently received Breakthrough Therapy Designation, accelerating development and review for this critical patient population
The licensed intellectual property covers methods and designs for CAR constructs engineered to function in myeloid cell populations
Evogene said ChemPass AI was significantly expanded during 2025 through internal development and collaborations with Google Cloud
Subscribe To Our Newsletter & Stay Updated
